Your partner for in vitro and in vivo services in oncology
ANTINEO SERVICES 2026
Reactivity, adaptability and flexibility
Advisory board of preclinical and clinical experts to understand your needs and projects
Established and characterized through RNAseq and immunophenotyping of the tumor microenvironment
To provide our customers with excellent value for money
A spin-off from an academic team at the Cancer Research Center of Lyon (CRCL)
10 years-old company
specialized in proof-of
concept studies in oncology
300+ studies
60+ sponsors
6 collaborative projects
Explore in vivo services
150+tumour models
(syngeneic, PDX, xenografts)30 models of secondary resistance to standards of care200cell lines
90 human & equal syngeneic
Up to 5 lasers and 29-markers panels Off the shelf or customized panels
Determination of IC50 / EC50
Continuous-monitoring studies
ADCC and ADCP assays
T cell activation by iFNy measurements
ADCC assays with fresh NK cells
Up to 5 lasers and 29-markers panels
Off the shelf or customized panels
Ensures precise extrusion bioprinting of standardized tumors models, enhancing reproducibility
Assessing live cell populations
in tumor models
Monitoring growth rates of various cell types
Analyzing responses to
targeted therapeutic agents
Creating complex environments
for accurate testing
They trust us : Pulsalys | Roche | Université de Tours | CRCL
« We have really benefited from Antineo expertise in preclinical services which has allowed us to establish proof of concept in xenograft models that they have identified, in-licensed and developed for us. Project management is very professionally done with regular reporting in a proactive mode. It is really nice to work with the whole team ! »
— Cécile Bougeret, Vice President of Operations, Evextabio
60F avenue Rockfeller
69008 Lyon FRANCE
2026 Antineo – All rights reserved | antineo.fr